510(k) device
TELLTALE Electrosurgical Guidewire System
Telltale, LLC · Percutaneous Catheter For Electrosurgical Cutting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures (SGO, Class II) · First FDA decision Nov 13, 2025, newest Nov 13, 2025Aortic stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
2
Naming "TELLTALE"
MAUDE reports
0
Brand "TELLTALE", since 2015
PubMed studies
566
Mentioning "TELLTALE"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- TELLTALE Electrosurgical Guidewire SystemBreakthrough510(k)
K252592 · Decided Nov 13, 2025 · 90 days after receipt
Device type: Percutaneous Catheter For Electrosurgical Cutting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures (SGO) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Tricuspid Valve Replacement (TTVR)National analysisReview closedCAG-00467NUpdated Sep 24, 2026
- Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve RegurgitationNational analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438NUpdated Sep 23, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National analysisReview closedCAG-00468NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "TELLTALE", any status and sponsor, newest update first.
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT05666713 · 90 participants · Start Feb 21, 2023 · Primary completion Feb 14, 2025
Device: TELLTALE BASILICA procedure · For: Valvular Heart Disease; Aortic Valve Failure
Sites: San Francisco, California; Fort Collins, Colorado; Washington D.C., District of Columbia · 10 sites in all
Phitogen Beauty Labs SRLNot on our public-company list
NCT07010549 · 24 participants · Start Sep 27, 2022 · Primary completion Feb 9, 2023
Device: Hyaluronic Acid injections · For: Skin Ageing
Sites: Genova, Italy
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TELLTALE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SGO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TELLTALE"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.